...the hybrid compound synthesis, testing the compounds in mouse models of AD and determining bioavailability. Neuro-Hitech Inc.'s...

...In exchange for $1.3 million in inventory credit and elimination of $6 million in debt, Neuro-Hitech...
...shares to David Ambrose, the sole shareholder of AMBI Pharmaceuticals Inc. and MCR Pharmaceuticals Inc. Neuro-Hitech...
...a 50.1% stake in Neuro-Hitech, was appointed vice chairman and may appoint two additional directors. Neuro-Hitech Inc....

...due on June 6, 2010; and 3 million shares worth about $1.4 million based on Neuro-Hitech’s...
...AMBI and MCR had combined revenues of about $2.7 million. Velocity Health Securities advised MCR. Neuro-Hitech...
...$9 million. Separately, Neuro-Hitech raised $3.0 million in a private offering of 12.1 million shares. Neuro-Hitech Inc....

...a Phase III trial (Study C119) to treat pain associated with HIV-distal sensory polyneuropathy (HIV-DSP) Neuro-Hitech...

...high-dose group did show a trend towards improvement on the latter endpoint vs. placebo (p=0.077). Neuro-Hitech Inc....

...an antihistamine in Russia (see B20). Medivation finished the week up $1.47 (10%) to $16.32. Neuro-Hitech...
...from the Huperzia serrata herb also failed to show significance on the study's secondary endpoints. Neuro-Hitech...

...Artisan Pharma Inc. , Waltham, Mass. Business: Cardiovascular Appointed: Gary Shearman, president and CEO of Neuro-Hitech Inc. WIR...